Drug Profile
Research programme: muscular dystrophy therapeutics - MyoTherix
Alternative Names: MRX 1043Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator MyoTherix
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA
- 01 Sep 2015 Preclinical trials in Duchenne muscular dystrophy in USA (unspecified route)